RegeneRx Biopharmaceuticals, Inc. To Present At Rodman & Renshaw Global Investment Conference

ROCKVILLE, Md., Sept. 2, 2015 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co.  The conference will be held September 8-10, 2015 at the St. Regis Hotel in New York City.  

Mr. Finkelstein will present on Thursday, September 10, 2015 at 10:50 a.m. ET. A live webcast of the presentation will be available at http://wsw.com/webcast/rrshq25/rgrx.  For those who are not available to listen to the live webcast, a replay will be archived on RegeneRx's website at http://regenerx.investorroom.com/events.

About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)

RegeneRx is focused on the development of a novel therapeutic peptide, TB4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in China, Pan Asia (Korea, Japan, and Australia, among others) and the U.S., and has an extensive worldwide patent portfolio covering its products.  RGN-259, the Company's TB4-based ophthalmic drug candidate, has been designated an orphan drug for the treatment of neurotrophic keratopathy (NK).  RegeneRx was recently allowed by the FDA to move into Phase III clinical trials with RGN-259 for the treatment of patients with NK and dry eye syndrome.  RegeneRx, through its U.S. joint venture, ReGenTree LLC, is developing RGN-259 in the United States and expects to initiate U.S. clinical trials in the third quarter of 2015.  RGN-352, the Company's TB4-based injectable drug candidate, is Phase 2-ready and developed to be administered systemically to prevent and restore tissue damage associated with acute events such as heart attacks, strokes, and other similar traumatic injuries.  For additional information about RegeneRx please visit www.regenerx.com.  

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.  There can be no assurance that any clinical trials will be initiated and completed within the estimated time frames or that any product candidates will ultimately result in commercial products.  Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2014, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/regenerx-to-present-at-rodman--renshaw-global-investment-conference-300136818.html

SOURCE RegeneRx Biopharmaceuticals, Inc.